NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/23/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization5.63 mln
Float1.79 mln
Earnings Date08/19/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
7.00
Transformational upside
Relative Strength
93
/ 100
Top performer
Debt / Equity
0.00
Debt-free
ROE
-183
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Adial Pharmaceuticals is a Virginia-based drug development company working to help people overcome addiction and manage pain without opioids. Its most advanced treatment, AD04, is currently in late-stage clinical trials aimed at reducing harmful alcohol use. Founded in 2010, the company continues to expand its pipeline of potential therapies targeting a range of conditions.
